Novartis Secures U.S. Approval for Pfizer-Rivaling Breast Cancer Drug

March 14, 2017

The U.S. Food and Drug Administration has approved Novartis' Kisqali, which is used to treat postmenopausal women who have a form of breast cancer that has been difficult to treat. The drug will challenge rival Pfizer's Ibrance as a first-line treatment for HR-positive, HER2-negative breast cancer.

Novartis has priced Kisqali, which it says has blockbuster potential, cheaper than Ibrance, with a 28-day supply, 600-mg dose costing $10,950, a 400-mg dose costing $8,760 and a 200-mg dose costing $4,380. The company estimates the meds' price at up to a 20 percent discount to Ibrance.

Kisqali is also under review in Europe.

Read the Reuters report